epcoritab-bysp (Epkinly) as a third-line treatment for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) of undetermined origin, including DLBCL and grade B cells caused by indolent
cells play a crucial role in the response to treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL). The Killer-Cell Immunoglobulin-Like Receptors (KIR) expressed on the surface
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) and is known to have a higher incidence among People Living With HIV (PLWH
Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that originates from the B-lymphocytes, which are a type of white blood cells responsible for producing antibodies that
Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of the non-HodgkinâÂ?Â?s lymphoma. We reported a case of 56-year-old woman with aggrresively growing
Statement of the problem: Diffuse Large B-Cell Lymphoma (DLBCL) is the most frequent B-cell Non-Hodgkin Lymphoma (B-NHL) which derives from Germinal Center (GC) B cells
CHOP chemotherapy in subjects with previously untreated activated B-cell (ABC) type Diffuse Large B-cell Lymphoma (DLBCL). The most commonly utilized immunohistochemistry (IHC) algorithm for DLBCL subtyping, developed
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) and is commonest in India. Targeting CD20+ cells by rituximab is therapy of choice
Background: In Diffuse Large B-cell Lymphoma is an aggressive heterogeneous form of Non-Hodgkin’s lymphoma. There is dreath of information in the demographics and overall survival ... Conclusion: There is inconsistency…
most prevalent Non-Hodgkin Lymphoma (NHL) is Diffuse Large B-Cell Lymphoma (DLBCL), with limited-stage DLBCL being classified as stage I or stage II illness. Advanced-stage DLBCL differs
Background: Primary cardiac CD5 positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL) with bcl-6 gene rearrangement is a rare subtype of DLBCL. The case is reported, along with
Background: Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathologic entity from diffuse large B-cell lymphoma. The optimal first-line therapy for PMBCL is subject of ongoing debate
types of lymphomas. We presented a case of discordant lymphomas composing simultaneous gastric diffuse large B-cell lymphoma and mixed cellularity Hodgkin lymphoma in stomach
discovery of common alterations across cases suffering from follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) have reported loss of heterozygosity (LOH) and deletions events targeting the 15q21
Diffuse large B-cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma
study the serum levels and lymph node tissue expression of YKL-40 in diffuse large B-cell lymphoma (DLBCL) patients to assess its prognostic value and shed light
dense-dose TMZ for 5 years without major side effects but later developed diffuse large B-cell lymphoma (DLBCL) and paraneoplastic pemphigus—highlighting potential underrecognized risks in long-term management
utilised in various combinations. We present the first instance of a primary cervical diffuse large B-cell lymphoma treated by an immediate hysteroscopic excision that has been documented
panCK, CD10. Ki-67 level was 95%. The diagnosis was set to diffuse large B-cell lymphoma involving retroperitoneal, peripheral, abdominal lymph nodes, lymph nodes of liver hilum and spleen
case of secondary, pancreatic, nodular involvement in a patient who suffered from a diffuse large B-cell lymphoma 3 years earlier. To better characterize this radiological finding, an endoscopic ultrasound
four cases have been documented worldwide. This is a case report of a confirmed B-cell lymphoma of the choroid plexus, the first reported case in the Philippines. This ... ventricular lavage and placement of ommaya…
Diffuse large B cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for 30-40% of the non- Hodgkin lymphoma. DLBCL has been demonstrated to be biologically heterogeneous. Gene ... profiling has…